Lyka Labs Limited (LYKALABS.NS)
NSE · INR · Healthcare · Biotechnology
₹78.40 (-1.99%) as of
Key statistics
- Market cap
- 2.83B
- EPS (TTM)
- -2.53
- Dividend yield
- 0.00%
- 52-week range
- 44.10 – 98.25
- Beta
- 0.58
- Revenue (TTM)
- 1.34B
- Profit margin
- -6.64%
- Volume
- 4.84k
About Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations for human and animal healthcare in India and internationally. It offers injectable critical care solutions, anti-infectives, antifungals, anti-ulcer therapies, oncology support, cardiovascular therapies, and women's healthcare solutions such as gonadotropins, hormonal therapies, and haematinic formulations. The company also develops pharmaceutical and nutritional solutions for livestock, poultry, equine, and companion animals. In addition, it engages in sterile injectable manufacturing, advanced lyophilization technology, liposomal drug delivery, quality assurance and quality control systems, and stability testing and validation services. The company offers its products in various forms, including lyophilized, liquid, and dry powder injections, as well as ointments, creams, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Mumbai, India
- Employees
- 648
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- PENNAR INDUSTRIES LTD. (PENIND.BO)
- CONNPLEX CINEMAS LIMITED (CONNPLEX-SM.NS)
- ORIENT CEMENT LTD (ORIENTCEM.BO)
- MAHINDRA EPC IRRIG LTD (MAHEPC.NS)
- SOLARIUM GREEN ENERGY LIMITED (SOLARIUM.BO)
- DHARA RAIL PROJECTS LTD (DHARARAIL-SM.NS)
- NEOCHEM BIO SOLUTIONS LTD (NEOCHEM-SM.NS)
- Capacit'e Infraprojects Limite (CAPACITE.BO)